[{"address1": "Clarence Thomas Building", "address2": "P.O. Box 4649 Road Town", "city": "Tortola", "zip": "VG1110", "country": "British Virgin Islands", "phone": "203 221 7378", "website": "https://www.portagebiotech.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.", "fullTimeEmployees": 7, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ian B. Walters M.B.A., M.D.", "age": 55, "title": "CEO & Chairman of Board", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 717885, "exercisedValue": 0, "unexercisedValue": 695213}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 7.37, "open": 7.73, "dayLow": 6.6848, "dayHigh": 8.118, "regularMarketPreviousClose": 7.37, "regularMarketOpen": 7.73, "regularMarketDayLow": 6.6848, "regularMarketDayHigh": 8.118, "beta": 96.713, "trailingPE": 0.2827869, "forwardPE": -13.269232, "volume": 95972, "regularMarketVolume": 95972, "averageVolume": 1787374, "averageVolume10days": 126720, "averageDailyVolume10Day": 126720, "bid": 6.75, "ask": 7.1, "bidSize": 100, "askSize": 100, "marketCap": 7236513, "fiftyTwoWeekLow": 2.1, "fiftyTwoWeekHigh": 53.2, "fiftyDayAverage": 4.7224, "twoHundredDayAverage": 8.8731, "currency": "USD", "enterpriseValue": 3238478, "floatShares": 594377, "sharesOutstanding": 1048760, "sharesShort": 9363, "sharesShortPriorMonth": 7187, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0089, "heldPercentInsiders": 0.36396998, "heldPercentInstitutions": 0.10769, "shortPercentOfFloat": 0.013300001, "bookValue": 2.394, "priceToBook": 2.8822055, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -71076000, "trailingEps": 24.4, "forwardEps": -0.52, "enterpriseToEbitda": -0.202, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PRTG", "underlyingSymbol": "PRTG", "shortName": "Portage Biotech Inc.", "longName": "Portage Biotech Inc.", "firstTradeDateEpochUtc": 1009981800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c85b618a-5b14-3e35-9d8d-d4e5ddb2236b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.9, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 3334000, "totalCashPerShare": 3.179, "ebitda": -16041000, "totalDebt": 37000, "quickRatio": 1.117, "currentRatio": 1.729, "debtToEquity": 2.044, "returnOnAssets": -0.19415002, "returnOnEquity": -1.9102901, "freeCashflow": -6336500, "operatingCashflow": -12530000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-10"}]